Abstract: The present invention is directed to methods and apparatus for creating a sustained release pathogen vaccine for COVID-19, influenza, HIV and other infectious human and animal viruses and pathogens using supercritical, critical, or near-critical fluids with or without polar cosolvents for simultaneously inactivating virions and pathogens, and encapsulating the inactivated virions and pathogens in biodegradable polymer nanospheres for administration to a patient. The present invention continuously inactivates SARS-CoV-2, influenza, HIV and other infectious human and animal viruses and pathogens, and nanoencapsulates the inactivated virions and pathogens in biodegradable polymer nanospheres to provide a safe and effective sustained-release vaccine, especially for the frail and elderly.

Abstract: This invention is for methods to quantify the inhibition of 5-HT induced contraction of human intestinal smooth muscle and an assay to measure the effects of compounds on nausea, irritable bowel syndrome and irritable bowel disease. This invention can be used to measure the incidence and severity of nausea, and can be used as quality control assay for developing and releasing medications for controlling nausea and emesis.

Abstract: This invention relates to a composition of matter using enhanced gingerols for treating nausea and emesis associated with cancer chemotherapy, pregnancy, elective surgery, radiation therapy, motion sickness, and drug medications, use and schedule of use as well as methods of making. A method of making the enhanced gingerols features supercritical, critical and near-critical fluids with and without polar cosolvents. The capsules include an enhanced extract of ginger rhizome wherein said ginger rhizome has a starting mass and said extract has a 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol mass and said ratio of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol mass to starting mass is 90-100%.

Abstract: Embodiments of the present invention feature novel Bryoid compositions, methods of making and methods of treating disease.

Abstract: Embodiments of the present invention are directed to dosage forms for treating inflammation and rejection in transplantation injuries, graft versus host disease and stem cell transplants with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.

Abstract: Embodiments of the present invention feature novel Bryoid compositions, methods of making and methods of treating disease.

Abstract: Embodiments of the present invention are directed to drug delivery systems, dosage forms and methods for the intranasal administration of Bryostatins for the treatment of neuro-degenerative diseases. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down syndrome and Alzheimer's disease.

Abstract: Embodiments of the present invention are directed to articles of manufacture and methods of making such articles having utility for the delivery of cannabinoids, naltrexone and a combination of cannabinoids and naltrexone as a therapeutic. One embodiment of the present invention directed to the article of manufacture comprises a lyophilized sphere having a diameter of about 100 to 500 nanometers having a shell comprising a biodegradable polymer containing a cannabinoid, naltrexone and a combination of a cannabinoid and naltrexone in a deareated buffer. A featured cannabinoid is cannabidiol (CBD).

Abstract: Embodiments of the present invention are directed to the administration of co-encapsulated bryostatins and retinoids for the treatment of disease, wherein the co-encapsulated bryostatins and retinoids synergistically increase expression of alpha secretase activity in patients. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson disease, Parkinson's disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes, cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and ophthalmic diseases such as glaucoma.

Abstract: Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.

Abstract: Embodiments of the present invention are directed to formulations and methods of treating folic acid deficiency and morning sickness. The dosage form has an effective amount, of a folic add with an effective amount of a gingerol composition to suppress nausea and/or gastric distress and to promote hematopoiesis.

Abstract: Embodiments of the present invention feature novel Bryoid compositions, methods of making and methods of treating disease.

Abstract: Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.

Abstract: Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.

Abstract: Embodiments of the present invention are directed to the oral administration of Bryostatins for the treatment of neuro-degenerative disease.

Abstract: This invention is for formulations of analogs of the non-toxic and inert Vitamin D3, its non-toxic and mostly inert pre-hormone and its toxic and biologically active hormone, and for using these formulations for preventing and treating certain cancers such as breast, prostate, ovarian, kidney, renal and other cancers, Vitamin D deficiency, autoimmune disease such as Multiple Sclerosis, hypertension, osteoporosis, bone diseases, rickets, psoriasis and infectious diseases. This invention also discloses compositions of the analogs of the non-toxic and inert Vitamin D3 and the non-toxic and mostly inert Vitamin D3 pre-hormone.

Abstract: Embodiments of the present invention are directed to methods and dosage forms for treating inflammation and rejection in transplantation injuries with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.

Abstract: Embodiments of the present invention are directed to an apparatus and methods for making nucleic acid loaded nanosomes. One embodiment of the present invention directed to an apparatus comprises a first containment means for containing a mixture of an aqueous solution of nucleic acid and a phospholipid solution with a supercritical, critical or near critical fluid. The apparatus further comprises injection means in fluid communication with said first containment means for receiving the mixture and releasing the mixture as a stream into a decompression liquid. The apparatus further comprises a decompression vessel in fluid communication with the injection means for holding a decompression liquid and receiving the mixture as a stream. The stream forms one or more nanosomes loaded with a nucleic acid in the decompression liquid.

Abstract: This invention is for formulations of analogs of the non-toxic and inert Vitamin D3, its non-toxic and mostly inert pre-hormone and its toxic and biologically active hormone, and for using these formulations for preventing and treating certain cancers such as breast, prostate, ovarian, kidney, renal and other cancers, Vitamin D deficiency, autoimmune disease such as Multiple Sclerosis, hypertension, osteoporosis, bone diseases, rickets, psoriasis and infectious diseases. This invention also discloses compositions of the analogs of the non-toxic and inert Vitamin D3 and the non-toxic and mostly inert Vitamin D3 pre-hormone.

Abstract: Embodiments of the present invention are directed to the administration of bryostatins and bryostatins and retinoids for the treatment of disease responsive to increases in alpha secretase activity. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes, cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and opthalmic diseases such as glaucoma.